TGM2 and glioblastoma: For example, TGM2 inhibitors have been shown to be effective in preclinical models of glioblastoma, where they cooperated with chemotherapy in reducing tumour growth by disrupting fibronectin assembly 44, while small molecules and antibodies targeting integrin–α5β1 are currently being used in clinical trials to block tumour angiogenesis 37.